News | February 07, 2024
IOL Chemicals and Pharmaceuticals net profit rises 43.5% in 9M FY24
The company recently received CEP certificate approval for Losartan Potassium by EDQM
The company recently received CEP certificate approval for Losartan Potassium by EDQM
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Delivers keynote address at the 4th convocation of AIIMS Jodhpur
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Revenue from Operations stood at Rs. 2,607 crore, 25% YoY growth. Domestic revenue at Rs. 2,400 crore, 20% YoY growth and export revenue at Rs. 207 crore, 118% YoY growth
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
